Patient characteristics, treatment patterns, survival and progression outcomes in patients with metastatic non‐small cell lung cancer receiving immune checkpoint inhibitors in combination with chemotherapy
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Antineoplastics (Primary) ; Atezolizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Dec 2020 New trial record